Interestingly, a recent study in pancreatic cancer cells showed that PLK1 inhibition enhances the effect of gemcitabine, also in gemcitabine‐resistant cells (Li et al., 2016). The gene discussed is PLK1; the disease is familial pancreatic carcinoma.